Open AccessACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Author(s) -
David M. Peereboom,
Justin D. Lathia,
Tyler Alban,
Alireza M. Mohammadi,
Manmeet S. Ahluwalia,
Cathy Brewer,
Michael Vogelbaum
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy148.044
Subject(s) - capecitabine , medicine , bevacizumab , immunosuppression , myeloid derived suppressor cell , glioma , cytotoxic t cell , cd8 , oncology , immune system , cancer research , cancer , gastroenterology , chemotherapy , immunology , suppressor , colorectal cancer , biology , in vitro , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom